NCT02486471

Brief Summary

Cytological abnormalities of the Cervix uteri need to be clarified by colposcopy biopsy. To avoid bleeding after biopsy, monsel´s paste is a common used Agent. In a randomized clinical Trial the use of monsel´s paste after biopsy will be compared to no Intervention. The Primary outcome of the study is blood loss, secondary outcomes are pain, satisfaction of the patient and influence of Independent factors such as Age and Body mass index.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
166

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2015

Shorter than P25 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 28, 2015

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 1, 2015

Completed
Same day until next milestone

Study Start

First participant enrolled

July 1, 2015

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2016

Completed
Last Updated

February 17, 2016

Status Verified

February 1, 2016

Enrollment Period

6 months

First QC Date

June 28, 2015

Last Update Submit

February 13, 2016

Conditions

Keywords

cervical dysplasiacolposcopyhaemostatic procedurebiopsy of the cervix uteri

Outcome Measures

Primary Outcomes (1)

  • Blood loss after 15 minutes (5-step visual analogue scale)

    blood loss 15 minutes after biopsy will be measured judging the amount of blood on the sanitary napkin (5-step visual analogue scale)

    15 minutes

Secondary Outcomes (6)

  • Blood loss after 3 hours (5-step visual analogue scale)

    3 hours

  • Blood loss after 6 hours (5-step visual analogue scale)

    6 hours

  • Blood loss after 24 hours (5-step visual analogue scale)

    24 hours

  • Sensation of pain after 15 minutes (10-step visual analogue scale)

    15 minutes

  • Overall Sensation of pain after 24 hours (10-step visual analogue scale)

    24 hours

  • +1 more secondary outcomes

Study Arms (2)

Observational approach

OTHER

Wait and see

Other: Wait and see

Use of Monsel´s Paste

ACTIVE COMPARATOR

cervical coagulation using a hemostatic agents, ie monsel´s paste

Procedure: Monsel´s Paste

Interventions

surgical method to stop bleeding by using the hemostatic Agent monsel´s paste until no more bleeding is visible

Use of Monsel´s Paste

finishing examination without hemostatic intervention, awaiting spontaneous coagulation

Observational approach

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • abnormal pap smear
  • first colposcopy ever

You may not qualify if:

  • pregnancy
  • bleeding disorder
  • the use of blood thinner
  • language barrier
  • unwillingness to participate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Zydolab - Institute of Cytology and Immune Cytochemistry

Dortmund, North Rhine-Westphalia, 44137, Germany

Location

Department of Obstetrics and Gynecology of the Ruhr University Bochum

Herne, North Rhine-Westphalia, 44625, Germany

Location

MeSH Terms

Conditions

Uterine Cervical Dysplasia

Interventions

Vision, Ocular

Condition Hierarchy (Ancestors)

Precancerous ConditionsNeoplasmsUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Intervention Hierarchy (Ancestors)

Light Signal TransductionSignal TransductionBiochemical PhenomenaChemical PhenomenaCell Physiological PhenomenaSensationNervous System Physiological PhenomenaMusculoskeletal and Neural Physiological PhenomenaOcular Physiological Phenomena

Study Officials

  • Ziad Hilal, M. D.

    Zydolab - Institute of Cytology and Immune Cytochemistry

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr. med. Ziad Hilal

Study Record Dates

First Submitted

June 28, 2015

First Posted

July 1, 2015

Study Start

July 1, 2015

Primary Completion

January 1, 2016

Study Completion

February 1, 2016

Last Updated

February 17, 2016

Record last verified: 2016-02

Data Sharing

IPD Sharing
Will not share

Locations